ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,231.05
0.59%
Dow Jones
38,122.51
-0.83%
Gold vs US Dollar
2,342.05
0.15%
Brent Oil
81.99
-1.66%
Bitcoin
69,233.78
2.44%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Halozyme Therapeutics Incorporated (HALO) Share Price

HALO Halozyme Therapeutics Incorporated

43.12
0.36 (0.84%)
Last Updated: 19:20:37
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Halozyme Therapeutics Incorporated NASDAQ:HALO NASDAQ Common Stock  
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   0.36 0.84 43.12 43.09 43.12 43.4799 42.62 42.94 276,684 18:20:37   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Biological Pds,ex Diagnstics 829.25M 281.59M 2.2203 19.41 5.47B
 Type  Size  Price  Time  Units 
 9 2 43.105 18:20:56 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore HALO News
22/05/202422:24EDGAR2Form 4 - Statement of changes in beneficial ownership of securities
22/05/202421:08EDGAR2Form 144 - Report of proposed sale of securities
21/05/202421:00EDGAR2Form 144 - Report of proposed sale of securities
21/05/202412:15PRNUSHalozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®
08/05/202413:30PRNUSHalozyme to Participate in Upcoming Investor Conferences
07/05/202421:09EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/05/202421:05EDGAR2Form 8-K - Current report
Period
Draw mode
Latest Message Board Discussions
DateTimeSource
Title
Posts
14/02/201908:08PBBRECOVERY STOCK @ 17.25p WITH BROKER TARGET OF 40p - HALOSOURCE (HALO)367
26/01/201511:01PBBHalosource - Clean water tech583
05/11/201410:17PBBGary Middleton, Director Lothbury Financial Services says to BUY in Halosource 2
10/04/201413:41PBBDO YOU OWN A SWIMMING POOL OR HOT TUB ?2
Data Downloads for HALO

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest Halozyme Therapeutics Incorporated Articles